After Friday's 16% gain, Moderna continues to surge on Wall Street. The company announced it is in the early stages of developing a hantavirus vaccine. Research began before the outbreak on the MV Hondius cruise ship.
Drugs and US stocks: Peter Mark, a key figure in overseeing vaccines, before leaving cited contrasts with the views of Robert F. Kennedy Jr, the new Secretary of Health chosen by Trump and a historic critic of vaccines
The Danish group saw a further increase in sales of drugs to fight diabetes and obesity. In the US, Moderna shares lead the decline of big tech. Kennedy is expected to take office as Secretary of Health this week
Faced with the decline of the pandemic and consequently of profits and stock market performance, the pharma giants compete in the courts: here's what's at stake
According to Moderna, Pfizer and BioNTech would have used the mRna technology deposited by the company between 2010 and 2016
Scientist Stéphane Bancel speaks and cools the enthusiasm of the markets: it will not be so easy to counter Omicron - more optimistic Pfizer with record turnover. But it is controversy with South Africa on the power of Big Pharma
Pharmaceuticals in free fall on Wall Street, with Moderna and BionTech losing almost 20% - Pfizer bucking the trend, which flies after the news on the anti-Covid drug
The third dose of the anti-Covid vaccine could soon become necessary for everyone - Reservations are open for some categories of citizens in the meantime - Here is the complete guide
After last Friday's sensational surge in the stock market, yesterday the shares of the two pharmaceutical companies collapsed under the ax of a devastating report by Bofa which defines their valuations as "ridiculous" - In reality, behind the business of…
While the hypothesis of the third dose against the Delta variant seems to take shape, the two pharmaceutical companies proceed to collect: according to the FT, they would have renegotiated the contracts with Brussels (which it neither confirms nor denies)
In the light of the positive data of the epidemiological curve and taking into account the millions of doses of vaccine arriving, the CTS has decided to administer the Oxford vaccine only to the over 60s and continue for the younger ones in…
AstraZeneca (and probably also J&J) will not be administered to the under 60s, therefore the plans of many countries change. Denmark suspends AstraZeneca definitively. EU-Pfizer agreement for 50 million new doses. The moves of France and Germany
What are the most effective vaccines in the fight against Covid? And which ones are easier to use? Here is a first evaluation, pending the Johnson & Johnson vaccine
Between vaccines, treatments and diagnostic tests, pharmaceutical stocks have been within the attention of investors for months. Who earned the most and why?
The operation, which must comply with the rules of the cold chain, concerns another 66 thousand doses and will be carried out by the Sda courier
The EMA, the European drug agency, has approved the vaccine of the Modern American who is preparing to land on the Old Continent
Phase 3 results indicate that the vaccine has an efficacy of 94,1% and even 100% in severe cases - Applications for authorization from the FDA and EMA today - Thiol soars on the stock market
As anticipated by President von der Leyen, the EU commission signs its sixth contract and expands the vaccine portfolio - Moderna headline on Wall Street - Speranza: "On December 2 I present the vaccine plan"
Pfizer's announcement of further effectiveness of its anti-Covid vaccine pleases the markets, especially the European ones and Piazza Affari is once again the best stock exchange - Banks and Generali also do well on its Investor Day
It is a battle between the two American giants for the anti Covid vaccine. A new announcement has arrived from Pfizer: "Phase 3 completed, 95% effectiveness. As the derby goes on, a surprise could come from the British AstraZeneca.
A preliminary agreement for 160 million doses - A total of six contracts signed by the EU for the anti Covid-19 vaccine
Moderna's anti-Covid vaccine transmits euphoria to the stock exchanges and also relaunches non-performing stocks: Piazza Affari also benefits, which collects a 2% increase in 22 weeks
Sparks on all the Stock Exchanges after the announcement of a vaccine by the American Moderna more effective and simpler than that of Pfizer - Wall Street opens sharply and Piazza Affari closes with an increase of almost 2% ...
